Salivary Therapeutic Monitoring of Buprenorphine in Neonates After Maternal Sublingual Dosing Guided by Physiologically Based Pharmacokinetic Modeling.

Published in: Therapeutic drug monitoring (2024)

Using neonatal saliva for buprenorphine therapeutic drug monitoring can facilitate newborn safety during the maternal treatment of OUD using sublingual buprenorphine. Nevertheless, the suitability of using adult values of respiratory depression EC 50 for newborns must be confirmed.

Keyphrases

birth weight
low birth weight
gestational age
pregnancy outcomes
allergic rhinitis
pregnant women
depressive symptoms
preterm infants
cord blood
physical activity
combination therapy